2. Search Result
Search Result
Results for "

low cytotoxic effect

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990688
    Xaluritamig

    AMG-509

    		 CD3 Cancer
    Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
    Xaluritamig
  • HY-N2452
    Cochinchinenin C

    		GLP Receptor Cardiovascular Disease Infection Metabolic Disease
    Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .
    Cochinchinenin C
  • HY-130178
    CL-385319

    		Endogenous Metabolite Infection
    CL-385319 is an N-substituted piperidine compound with inhibitory activity against H5N1 avian influenza A virus infection. CL-385319 exhibited an IC50 of 27.03±2.54 μM against infection of highly pathogenic H5N1 virus in Madin-Darby canine kidney cells (MDCK). CL-385319 had low cytotoxicity with a CC50 of 1.48 mM and was able to inhibit the entry of pseudoviruses carrying H5N1 strains from different sources, but had no inhibitory effect on the entry of VSV-G pseudotyped particles. Pseudoviruses with the M24A mutation in HA1 or the F110S mutation in HA2 were resistant to CL-385319, indicating that these two residues in the cavity region may be critical for the binding of CL-385319 .
    CL-385319
  • HY-P5640
    Tritrpticin

    		Bacterial Parasite Infection
    Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against *Trichomonas vaginalis*, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia .
    Tritrpticin
  • HY-130612
    PROTAC BRD2/BRD4 degrader-1

    		Epigenetic Reader Domain PROTACs Cancer
    PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein BRD4 and BRD2 degrader, connected by ligands for Cereblon and BET. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3. It effectively inhibits solid tumors with low cytotoxic effect. PROTAC BRD2/BRD4 degrader-1 is composed of the BET inhibitor, a linker, and the ligand thalidomide for cereblon (CRBN)/cullin 4A .
    PROTAC BRD2/BRD4 degrader-1
  • HY-172264
    XT17

    		Antibiotic Bacterial DNA/RNA Synthesis Infection
    XT17 is an anthrone compound with broad-spectrum antibacterial activity. It exerts its antibacterial effect by disrupting the cell wall and inhibiting DNA synthesis. XT17 exhibits weak hemolytic activity, low cytotoxicity against mammalian cell lines, and a low frequency of drug resistance. Meanwhile, XT17 shows in vivo efficacy in a mouse corneal infection model induced by Staphylococcus aureus or Pseudomonas aeruginosa. Further docking studies have confirmed that XT17 can form a stable complex with bacterial gyrase. XT17 can be used in the research of the anti - infection field .
    XT17
  • HY-176217
    dA-NHbenzylOCF3

    		Biochemical Assay Reagents DNA/RNA Synthesis Cancer
    dA-NHbenzylOCF3 is a DNA-targeted radiosensitizer that enhances the sensitivity of tumor cells to X-rays via the dissociative electron attachment (DEA) mechanism. dA-NHbenzylOCF3 shows low cytotoxicity to normal cells and mainly localizes to the cytoplasm and nucleus after entering cells. dA-NHbenzylOCF3 exerts its radiosensitizing effect by inducing cell cycle arrest at the radiation-sensitive G2/M phase. dA-NHbenzylOCF3 can be used for radiosensitization research on malignant tumors such as prostate cancer and breast cancer .
    dA-NHbenzylOCF3
  • HY-17648
    MBL-II-141

    		BCRP Cancer
    MBL-II-141 is potent ABCG2 inhibitor with an IC50 of 0.11 μM. MBL-II-141 inhibits the transport function of ABCG2 in a non-competitive manner, preventing ABCG2 from pumping substrates (such as Irinotecan (HY-16562)) out of the cells, thereby increasing the accumulation of drugs within the cells. MBL-II-141 has no effect on ABCB1 (P-gp) and ABCC1 (MRP1) and has extremely low cytotoxicity (IG50 > 100 μM). MBL-II-141 can be used for the study of multidrug resistance (MDR) cancers .
    MBL-II-141
  • HY-146197
    Apoptotic agent-1

    		Apoptosis Cancer
    Apoptotic agent-1 (Compound 8a) is an apoptotic agent with high antiproliferative activity against cancer cells and low cytotoxic effect. Apoptotic agent-1 induces over-expression of Fas receptor and Cyto C genes .
    Apoptotic agent-1
  • HY-142694
    DCN1-UBC12-IN-2

    		E1/E2/E3 Enzyme Cardiovascular Disease
    DCN1-UBC12-IN-2 is a potent and specific DCN1-UBC12 inhibitor (IC50=9.55 nM). DCN1-UBC12-IN-2 could specifically target DCN1-UBC12 interaction and relieve Ang II-induced cardiac fibroblast activation .
    DCN1-UBC12-IN-2
  • HY-142691
    DCN1-UBC12-IN-1

    		E1/E2/E3 Enzyme Cardiovascular Disease
    DCN1-UBC12-IN-1 is potent and selective DCN1-UBC12 inhibitor with an IC50 of 2.86 nM. Anticardiac fibrotic effect .
    DCN1-UBC12-IN-1
  • HY-142692
    DCN1-UBC12-IN-3

    		E1/E2/E3 Enzyme Cardiovascular Disease
    DCN1-UBC12-IN-3 is potent and selective DCN1-UBC12 inhibitor with an IC50 of 2.25 nM. Anticardiac fibrotic effect .
    DCN1-UBC12-IN-3
  • HY-153690
    Progranulin modulator-1

    		TNF Receptor Others
    Progranulin modulator-1 (Compound 60) is an orally active enhancer of progranulin (PGRN) secretion. Progranulin modulator-1 enhances the potency of BV-2 cell to increase PGRN levels, has inhibitory effect on hERG and Low cytotoxicity, the PGRN EC50 and hERG IC50 were 83 and 3100 nM, respectively .
    Progranulin modulator-1
  • HY-147556
    SK3 Channel-IN-1

    		Potassium Channel Cancer
    SK3 Channel-IN-1 (compound 7a) is a potent and specific SK3 channel modulator. SK3 Channel-IN-1 has efficient effect on breast cancer MDA-MB-435 cell migration while exhibiting low cytotoxicity in other cell lines. SK3 Channel-IN-1 can modulate ion channels’activity in cancer .
    SK3 Channel-IN-1
  • HY-144334
    CHIKV-IN-3

    		CHIKV DNA/RNA Synthesis Infection
    CHIKV-IN-3 is a potent against two low-passage CHIKV inhibitor with EC50 values of 1.55 and 0.14 μM for CHIKV-122508 and CHIKV-6708, respectively. CHIKV-IN-3 acts on the host cells to interfere with the viral replication. CHIKV-IN-3 displays minimal cytotoxic liability (CC50>100 μM). Prophylactic effect .
    CHIKV-IN-3
  • HY-162492
    Influenza A virus-IN-14

    		Influenza Virus Infection
    Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC50 of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC50 of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .
    Influenza A virus-IN-14
  • HY-172965
    SARS-CoV-2 Mpro-IN-43

    		SARS-CoV Virus Protease Infection Inflammation/Immunology
    SARS-CoV-2 Mpro-IN-43 (Compound 1) is a coronavirus main protease (Mpro) inhibitor (IC50: 72 μM). SARS-CoV-2 Mpro-IN-43 interacts with key residues in the active site of Mpro via non-covalent binding, exerting its anti-coronavirus effect. SARS-CoV-2 Mpro-IN-43 exhibits moderate to low cytotoxicity, with CC50 values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 can be used in anti-SARS-CoV-2 research .
    SARS-CoV-2 Mpro-IN-43
  • HY-121642
    SL-017

    		Others Others
    SL-017 is a novel photoacoustic sensitizer and a derivative of photofrin B. It can be taken up by cells to the maximum extent within 30 minutes and is mainly localized in mitochondria. After being activated by visible light or ultrasound, SL-017 can significantly increase the production of reactive oxygen species (ROS). Low concentrations of SL-017 can rapidly cause the loss of mitochondrial membrane potential. SL-017 can also cause mitochondrial fragmentation, a process that occurs after the loss of membrane potential. Epoxyeicosatrienoic acids (EETs) can alleviate the loss of mitochondrial membrane potential caused by SL-017, but the antioxidant ascorbic acid has no such effect. These characteristics indicate that SL-017 mainly targets mitochondria and exerts its cytotoxic effect by triggering the collapse of mitochondrial membrane potential, generating ROS, and causing mitochondrial fragmentation. As a novel photoacoustic sensitizer, SL-017 has potential application value in photodynamic therapy and sonodynamic therapy.
    SL-017
  • HY-P11241
    oNCM

    		Bacterial Infection Inflammation/Immunology
    oNCM is an antibacterial peptide. oNCM has good antibacterial activity, anti biofilm ability, anti-inflammatory effect, high stability, and low cytotoxicity. oNCM can be used for research on infectious or inflammatory conditions .
    oNCM
  • HY-175309
    URAT1-IN-14

    		URAT1 Metabolic Disease
    URAT1-IN-14 is a potent and orally active Urate transporter 1 (URAT1) inhibitor. URAT1-IN-14 inhibits the human URAT1 in HEK293 cells with an IC50 of 0.72 μM. URAT1-IN-14 exhibits low cytotoxic in Hep-G2 cells. URAT1-IN-14 shows urate-lowering effect in hyperuricemia mouse models. URAT1-IN-14 can be used for the study of hyperuricemia and gout .
    URAT1-IN-14
  • HY-180194
    SERCA2a activator 2

    		Calcium Channel Cardiovascular Disease
    SERCA2a activator 2 (Compound 25) is a potent SERCA2a (cardiac type) activator, which also has an activating effect on SERCA1a (skeletal muscle type). SERCA2a activator 2, under [Ca²⁺]MAX conditions activates the ATPase activity of SERCA2a and promotes Ca²⁺ uptake, with its EC₅₀ values being 4 μM and 0.80 μM respectively. SERCA2a activator 2 also exhibits consistent activating effects under more physiological [Ca²⁺]MID conditions. SERCA2a activator 2 has low cytotoxicity and can be used for research on diseases such as heart failure .
    SERCA2a activator 2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: